In a study looking at low-grade gliomas, Metellus and colleagues demonstrated that tumours harbouring the IDH1 mutation are smaller and less likely to have an infiltrative pattern on MRI.[6] Similarly, Carrillo and colleagues found that IDH1-positive glioblastomas were non-CE and were more likely to be located in the frontal lobe.[5] Recently, MR spectroscopy has been used to identify mutant tumours through the non-invasive detection of the 2-hydroxyglutarate.[11, 12] In the present study we also found that the majority of IDH1-R132H positive tumours (55%) were located in the frontal lobe. Here, IDH1 is linked to central nervous system cancer.